May 31, 2022 7:00am EDT Tonix Pharmaceuticals Announces Two Oral Presentations Involving TNX-1500 (Fc-modified anti-CD40L mAb) on Prevention of Rejection in Kidney and Heart Allograft Transplantation at the 2022 American Transplant Congress
May 18, 2022 7:00am EDT Tonix Pharmaceuticals Extends Research Collaboration with the University of Alberta to Develop Antiviral Drugs Against SARS-CoV-2
May 9, 2022 7:00am EDT Tonix Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights
Apr 25, 2022 7:00am EDT Tonix Pharmaceuticals to Present at B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference
Apr 20, 2022 7:00am EDT Tonix Pharmaceuticals Announces Results of Retrospective Observational Database Study In Over 50,000 Long COVID Patients
Apr 7, 2022 7:00am EDT Tonix Pharmaceuticals Initiates Enrollment in the RESILIENT Study, a Potentially Pivotal Phase 3 Study of TNX-102 SL for the Management of Fibromyalgia
Apr 6, 2022 7:00am EDT Tonix Pharmaceuticals Announces IND Clearance for TNX-102 SL as a Potential Treatment for Long COVID Syndrome, Also Known as Post-Acute Sequelae of COVID-19 (PASC)
